Pharma’s interest in using big data to demonstrate the value of its medicines and efforts to expand services to patients beyond the pill are resulting in more deals between biopharma and non-traditional partners like digital health firms, data management companies and other service providers.
The Rise Of The Alt-Deal
As the pharmaceutical industry works to manage big data, improve the way drugs are used and delivered, and expand services to patients, industry is working increasingly with non-traditional partners.